• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用[18F]THK - 5351对认知正常的老年人和阿尔茨海默病患者中tau蛋白积累的动态PET测量。

Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer's Disease Patients Measured Using [18F] THK-5351.

作者信息

Lockhart Samuel N, Baker Suzanne L, Okamura Nobuyuki, Furukawa Katsutoshi, Ishiki Aiko, Furumoto Shozo, Tashiro Manabu, Yanai Kazuhiko, Arai Hiroyuki, Kudo Yukitsuka, Harada Ryuichi, Tomita Naoki, Hiraoka Kotaro, Watanuki Shoichi, Jagust William J

机构信息

Helen Wills Neuroscience Institute, University of California, Berkeley, California, United States of America.

Center of Functional Imaging, Lawrence Berkeley National Laboratory, Berkeley, California, United States of America.

出版信息

PLoS One. 2016 Jun 29;11(6):e0158460. doi: 10.1371/journal.pone.0158460. eCollection 2016.

DOI:10.1371/journal.pone.0158460
PMID:27355840
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4927104/
Abstract

BACKGROUND

[18F]THK5351, a recently-developed positron emission tomography (PET) tracer for measuring tau neurofibrillary tangle accumulation, may help researchers examine aging, disease, and tau pathology in living human brains. We examined THK5351 tracer pharmacokinetics to define an optimal acquisition time for static late images.

METHODS

Primary measurements were calculation of regional values of distribution volume ratios (DVR) and standardized uptake value ratios (SUVR) in 6 healthy older control and 10 Alzheimer's disease (AD) participants. We examined associations between DVR and SUVR, searching for a 20 min SUVR time window that was stable and comparable to DVR. We additionally examined diagnostic group differences in this 20 min SUVR.

RESULTS

In healthy controls, [18F]THK5351 uptake was low, with increased temporal relative to frontal binding. In AD, regional uptake was substantially higher than in healthy controls, with temporal exceeding frontal binding. Retention in cerebellar gray matter, which was used as the reference region, was low compared to other regions. Both DVR and SUVR values showed minimal change over time after 40 min. SUVR 20-40, 30-50, and 40-60 min were most consistently correlated with DVR; SUVR 40-60 min, the most stable time window, was used in further analyses. Significant (AD > healthy control) group differences existed in temporoparietal regions, with marginal medial temporal differences. We found high basal ganglia SUVR 40-60 min signal, with no group differences.

CONCLUSIONS

We examined THK5351, a new PET tracer for measuring tau accumulation, and compared multiple analysis methods for quantifying regional tracer uptake. SUVR 40-60 min performed optimally when examining 20 min SUVR windows, and appears to be a practical method for quantifying relative regional tracer retention. The results of this study offer clinical potential, given the usefulness of THK5351-PET as a biomarker of tau pathology in aging and disease.

摘要

背景

[18F]THK5351是一种最近开发的用于测量tau神经原纤维缠结积聚的正电子发射断层扫描(PET)示踪剂,可能有助于研究人员检查活体人类大脑中的衰老、疾病和tau病理。我们研究了THK5351示踪剂的药代动力学,以确定静态晚期图像的最佳采集时间。

方法

主要测量是计算6名健康老年对照者和10名阿尔茨海默病(AD)参与者的分布体积比(DVR)和标准化摄取值比(SUVR)的区域值。我们研究了DVR和SUVR之间的关联,寻找一个稳定且与DVR相当的20分钟SUVR时间窗。我们还研究了这个20分钟SUVR中的诊断组差异。

结果

在健康对照者中,[18F]THK5351摄取较低,颞叶相对于额叶的结合增加。在AD患者中,区域摄取明显高于健康对照者,颞叶超过额叶结合。与其他区域相比,用作参考区域的小脑灰质中的滞留较低。40分钟后,DVR和SUVR值随时间的变化都很小。SUVR 20 - 40、30 - 50和40 - 60分钟与DVR的相关性最一致;SUVR 40 - 60分钟是最稳定的时间窗,用于进一步分析。颞顶叶区域存在显著的(AD > 健康对照)组间差异,内侧颞叶差异不显著。我们发现基底神经节SUVR 40 - 60分钟信号较高,无组间差异。

结论

我们研究了用于测量tau积聚的新型PET示踪剂THK5351,并比较了多种定量区域示踪剂摄取的分析方法。在检查20分钟SUVR时间窗时,SUVR 40 - 60分钟表现最佳,似乎是一种定量相对区域示踪剂滞留的实用方法。鉴于THK5351 - PET作为衰老和疾病中tau病理生物标志物的有用性,本研究结果具有临床潜力。

相似文献

1
Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer's Disease Patients Measured Using [18F] THK-5351.使用[18F]THK - 5351对认知正常的老年人和阿尔茨海默病患者中tau蛋白积累的动态PET测量。
PLoS One. 2016 Jun 29;11(6):e0158460. doi: 10.1371/journal.pone.0158460. eCollection 2016.
2
In Vivo Comparison of Tau Radioligands F-THK-5351 and F-THK-5317.Tau放射性配体F-THK-5351和F-THK-5317的体内比较
J Nucl Med. 2017 Jun;58(6):996-1002. doi: 10.2967/jnumed.116.182980. Epub 2016 Nov 10.
3
Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology.(S)-¹⁸F-THK5117 作为评估 Tau 病理学的 PET 示踪剂的示踪动力学分析。
J Nucl Med. 2016 Apr;57(4):574-81. doi: 10.2967/jnumed.115.158519. Epub 2016 Jan 21.
4
Monoamine oxidase B inhibitor, selegiline, reduces F-THK5351 uptake in the human brain.单胺氧化酶B抑制剂司来吉兰可降低人脑中F-THK5351的摄取。
Alzheimers Res Ther. 2017 Mar 31;9(1):25. doi: 10.1186/s13195-017-0253-y.
5
Differences in gray and white matter F-THK5351 uptake between behavioral-variant frontotemporal dementia and other dementias.行为变异型额颞叶痴呆与其他痴呆症之间的灰质和白质 F-THK5351 摄取的差异。
Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):357-366. doi: 10.1007/s00259-018-4125-x. Epub 2018 Aug 14.
6
Tau PET imaging with F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study.阿尔茨海默病患者与健康对照者中 F-PI-2620 的 Tau PET 成像:首例人体研究。
J Nucl Med. 2020 Jun;61(6):911-919. doi: 10.2967/jnumed.119.236224. Epub 2019 Nov 11.
7
In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls.在体鉴定和定量研究人类神经纤维缠结 Tau PET 放射性配体 F-MK-6240 从阿尔茨海默病痴呆到年轻对照的变化。
J Nucl Med. 2019 Jan;60(1):93-99. doi: 10.2967/jnumed.118.209650. Epub 2018 May 18.
8
Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.18F-MK-6240 tau 缠结的纵向积累遵循 Braak 分期。
Brain. 2021 Dec 16;144(11):3517-3528. doi: 10.1093/brain/awab248.
9
18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease.18F-THK5351:一种用于阿尔茨海默病神经纤维病理成像的新型正电子发射断层显像剂。
J Nucl Med. 2016 Feb;57(2):208-14. doi: 10.2967/jnumed.115.164848. Epub 2015 Nov 5.
10
Evaluation of Dosimetry, Quantitative Methods, and Test-Retest Variability of F-PI-2620 PET for the Assessment of Tau Deposits in the Human Brain.评估 F-PI-2620 PET 用于评估人类大脑 Tau 沉积物的剂量学、定量方法和复测变异性。
J Nucl Med. 2020 Jun;61(6):920-927. doi: 10.2967/jnumed.119.236240. Epub 2019 Nov 11.

引用本文的文献

1
Tau Imaging: Use and Implementation in New Diagnostic and Therapeutic Paradigms for Alzheimer's Disease.tau蛋白成像:在阿尔茨海默病新诊断和治疗模式中的应用与实施
Geriatrics (Basel). 2025 Feb 14;10(1):27. doi: 10.3390/geriatrics10010027.
2
Reproducibility of [F]MK-6240 kinetics in brain studies with shortened dynamic PET protocol in healthy/cognitively normal subjects.在健康/认知正常受试者中采用缩短动态PET方案进行脑研究时,[F]MK-6240动力学的可重复性。
EJNMMI Phys. 2024 Sep 27;11(1):79. doi: 10.1186/s40658-024-00679-3.
3
Heterogeneity of factors associated with cognitive decline and cortical atrophy in early- versus late-onset Alzheimer's disease.

本文引用的文献

1
18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease.18F-THK5351:一种用于阿尔茨海默病神经纤维病理成像的新型正电子发射断层显像剂。
J Nucl Med. 2016 Feb;57(2):208-14. doi: 10.2967/jnumed.115.164848. Epub 2015 Nov 5.
2
Tau imaging: early progress and future directions.tau 成像:早期进展与未来方向。
Lancet Neurol. 2015 Jan;14(1):114-24. doi: 10.1016/S1474-4422(14)70252-2.
3
Primary age-related tauopathy (PART): a common pathology associated with human aging.原发性年龄相关性tau蛋白病(PART):一种与人类衰老相关的常见病理状态。
早发性与晚发性阿尔茨海默病认知衰退和皮质萎缩相关因素的异质性。
Sci Rep. 2024 Sep 3;14(1):20429. doi: 10.1038/s41598-024-71402-6.
4
Associations of tau, Aβ, and brain volume of the Papez circuit with cognition in Alzheimer's disease.阿尔茨海默病中tau蛋白、β淀粉样蛋白以及帕佩兹环路脑容量与认知的关联。
Eur Arch Psychiatry Clin Neurosci. 2025 Feb;275(1):241-256. doi: 10.1007/s00406-024-01827-7. Epub 2024 Jun 2.
5
Neuroimaging modalities in the detection of Alzheimer's disease-associated biomarkers.用于检测阿尔茨海默病相关生物标志物的神经成像模态
Psychoradiology. 2023 Jun 22;3:kkad009. doi: 10.1093/psyrad/kkad009. eCollection 2023.
6
Tau: a biomarker of Huntington's disease.tau:亨廷顿病的生物标志物。
Mol Psychiatry. 2023 Oct;28(10):4070-4083. doi: 10.1038/s41380-023-02230-9. Epub 2023 Sep 25.
7
Alzheimer's disease is an inherent, natural part of human brain aging: an integrated perspective.阿尔茨海默病是人类大脑自然老化的固有组成部分:综合视角。
Free Neuropathol. 2022 Jul 8;3:17. doi: 10.17879/freeneuropathology-2022-3806. eCollection 2022 Jan.
8
Toward standardization of tau PET imaging corresponding to various tau PET tracers: a multicenter phantom study.针对各种 tau PET 示踪剂的 tau PET 成像标准化:一项多中心体模研究。
Ann Nucl Med. 2023 Sep;37(9):494-503. doi: 10.1007/s12149-023-01847-8. Epub 2023 May 27.
9
The Sensitivity of Tau Tracers for the Discrimination of Alzheimer's Disease Patients and Healthy Controls by PET.正电子发射断层扫描(PET)中 tau 示踪剂对阿尔茨海默病患者与健康对照者的区分敏感性。
Biomolecules. 2023 Feb 3;13(2):290. doi: 10.3390/biom13020290.
10
Time-varying SUVr reflects the dynamics of dopamine increases during methylphenidate challenges in humans.时间变化的 SUVr 反映了人类在哌甲酯挑战期间多巴胺增加的动态。
Commun Biol. 2023 Feb 10;6(1):166. doi: 10.1038/s42003-023-04545-3.
Acta Neuropathol. 2014 Dec;128(6):755-66. doi: 10.1007/s00401-014-1349-0. Epub 2014 Oct 28.
4
Tau PET imaging in Alzheimer's disease.阿尔茨海默病中的 Tau 蛋白正电子发射断层显像
Curr Neurol Neurosci Rep. 2014 Nov;14(11):500. doi: 10.1007/s11910-014-0500-6.
5
Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.使用 18F-THK5105 PET 进行阿尔茨海默病神经纤维缠结的无创评估。
Brain. 2014 Jun;137(Pt 6):1762-71. doi: 10.1093/brain/awu064. Epub 2014 Mar 27.
6
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls.tau 病小鼠模型和阿尔茨海默病患者与正常对照的 tau 病理学成像比较。
Neuron. 2013 Sep 18;79(6):1094-108. doi: 10.1016/j.neuron.2013.07.037.
7
Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease.新型 18F 标记芳基喹啉衍生物用于阿尔茨海默病 tau 病理的无创成像。
J Nucl Med. 2013 Aug;54(8):1420-7. doi: 10.2967/jnumed.112.117341. Epub 2013 Jul 15.
8
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.阿尔茨海默病病理生理过程的追踪:动态生物标志物的更新假设模型。
Lancet Neurol. 2013 Feb;12(2):207-16. doi: 10.1016/S1474-4422(12)70291-0.
9
Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807.新型 PHF-tau 放射性配体 [F-18]-T807 的早期临床 PET 成像结果。
J Alzheimers Dis. 2013;34(2):457-68. doi: 10.3233/JAD-122059.
10
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.阿尔茨海默病神经病理变化与认知状态的相关性:文献综述。
J Neuropathol Exp Neurol. 2012 May;71(5):362-81. doi: 10.1097/NEN.0b013e31825018f7.